June 20, 2025 a 05:01 pm
PFE: Analysts Ratings - Pfizer Inc.
Pfizer Inc. has maintained a stable foothold in the biopharmaceutical sector, characterized by a strong product pipeline and strategic collaborations. Despite market fluctuations, analysts show a cautious sentiment towards PFE, with a shift towards more conservative recommendations. The company's diversified therapeutic offerings and global presence play a crucial role in its market evaluation.
Historical Stock Grades
In June 2025, Pfizer's analyst ratings indicate a slightly cautious stance, with a substantial portion of ratings being Hold. This suggests that analysts are adopting a more watchful approach, possibly due to market uncertainties or valuation concerns.
| Rating | Count | Score |
|---|---|---|
| Strong Buy | 2 | |
| Buy | 7 | |
| Hold | 15 | |
| Sell | 1 | |
| Strong Sell | 0 |
Sentiment Development
Over recent months, the sentiment towards Pfizer has displayed a shift towards more conservative ratings. The overall number of Buy ratings has decreased, and Hold ratings have increased significantly. This may indicate a growing uncertainty about Pfizer's near-term performance or market conditions.
- Steady rise in Hold ratings from 13 to 15 in the recent months.
- Reduction in the number of Strong Buy ratings from 3 to 2 between March and June 2025.
- Sell and Strong Sell ratings remain low and stable, indicating limited negative sentiment.
Percentage Trends
The percentage distribution of analyst ratings for Pfizer Inc. suggests a more cautious approach, with a noticeable increase in Hold ratings and a slight decrease in the percentage of Buy ratings:
- Strong Buy ratings decreased from 10% to around 9%.
- Buy ratings edged down from 31% to about 22%.
- Hold ratings increased significantly from 59% to 65%.
- Sell and Strong Sell ratings unchanged, indicating minimal pessimism.
- This highlights a trend towards more neutral sentiment, with fewer outright buy recommendations.
Latest Analyst Recommendations
The recent analyst recommendations for Pfizer largely suggest a holding pattern, with some downgrades indicating cautious optimism is waning slightly:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-04-30 | Neutral | Neutral | UBS |
| 2025-04-08 | Neutral | Buy | Goldman Sachs |
| 2025-04-08 | Neutral | Neutral | UBS |
| 2025-03-18 | Buy | Buy | Guggenheim |
| 2025-03-12 | Buy | Buy | Guggenheim |
Analyst Recommendations with Change of Opinion
The analyst community has shown some shifts in perspective regarding Pfizer Inc., with notable downgrades and a few upgrades within the past year:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-04-08 | Neutral | Buy | Goldman Sachs |
| 2024-08-08 | Outperform | Neutral | Daiwa Capital |
| 2024-03-22 | Hold | Buy | Argus Research |
| 2024-01-04 | Market Perform | Outperform | TD Cowen |
| 2023-10-16 | Buy | Hold | Jefferies |
Interpretation
The recent trends in analyst ratings for Pfizer Inc. indicate a movement towards conservative positions, with more Neutral and Hold evaluations. This shift may suggest growing concerns about market volatility or Pfizer's strategic challenges. However, the stability in ratings distribution shows a lack of severe negative sentiment. Such trends imply an environment of cautious engagement, with analysts awaiting further financial or operational catalysts before making affirmative Buy recommendations.
Conclusion
In summary, Pfizer Inc. is experiencing a period of evaluative caution by analysts. The shift towards more Hold ratings indicates a period of scrutiny and moderation, likely influenced by market dynamics and company-specific factors. While Pfizer maintains leading positions in key therapeutics and collaborations, the current market sentiment reflects mixed expectations. Investors may see this as an opportunity to assess Pfizer’s long-term strategic developments amidst transient market sentiments.